Use of zoledronic acid reduces a long-term risk for skeletal complications in patients with cancer of the kidney or urinary bladder

P. F. Mulders; K. Miller; N. S. Tchekmedyian

doi:10.17650/1726-9776-2008-4-1-55

Use of zoledronic acid reduces a long-term risk for skeletal complications in patients with cancer of the kidney or urinary bladder

P. F. Mulders, K. Miller, N. S. Tchekmedyian

https://doi.org/10.17650/1726-9776-2008-4-1-55

Full Text:

PDF (Rus)

Generate QR code

Abstract
About the Authors
Cited By
Scopus Cited

About the Authors

P. F. Mulders

University Hospital Nijmegen
Netherlands

K. Miller

Universitatsklinikum Benjamin Franklin
Germany
Berlin

N. S. Tchekmedyian

Pacific Shores Medical Group
United States
Long Beach

Review

For citations:

Mulders P.F., Miller K., Tchekmedyian N.S. Use of zoledronic acid reduces a long-term risk for skeletal complications in patients with cancer of the kidney or urinary bladder. Cancer Urology. 2008;4(1):55. (In Russ.) https://doi.org/10.17650/1726-9776-2008-4-1-55

This work is licensed under a Creative Commons Attribution 4.0 License.

ISSN 1726-9776 (Print)
ISSN 1996-1812 (Online)

Username
Password
	Remember me
Not a user? Register with this site Forgot your password?

User

Cancer Urology

Use of zoledronic acid reduces a long-term risk for skeletal complications in patients with cancer of the kidney or urinary bladder

Full Text:

About the Authors

Review

For citations:

Cookies policy